Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer

• DOI: 10.1186/s12967-019-1782-x
• Publication Date: 2019-01-18T08:02:56Z
• Authors: Ke Zhang; Yong-Qiang Hua; Dan Wang; Lian-Yu Chen; Cai-Jun Wu; Zhen Chen; Lu-Ming Liu; Hao Chen
• Keywords: Aspartate transaminase; Univariate analysis; Absolute neutrophil count

Systemic inflammation and immune dysfunction have been proved to be associated with cancer progression metastasis in various malignancies. The aim of this retrospective study was evaluate the prognostic significance pre-treatment systemic immune-inflammation index (SII) patients advanced pancreatic cancer. In total, 419 diagnosed cancer, between January 2011 December 2015, were retrospectively enrolled. SII developed based on a training set 197 from 2013 validated an independent cohort 222 2014 2015. Data baseline clinicopathologic characteristics; laboratory variables such as absolute neutrophil, lymphocyte, platelet counts; carbohydrate antigen 19-9 (CA19-9), total bilirubin (TBIL), albumin (ALB), alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate (AST) levels collected. association characteristics assessed. overall survival calculated using Kaplan–Meier curves compared log-rank test. Univariate multivariate Cox proportional hazard regression models used analyze value SII. An optimal cutoff point for 440 stratified into high (> 440) low (≤ groups cohort. analyses revealed that predictor survival. confirmed both normal elevated CA19-9 levels. serves marker can